Redenlab Supporting PTC Theraputics in Global Phase 3 Clinical Trial

Redenlab are proud to be supporting PTC Therapeutics, Inc. Global Phase 3 Clinical Trial to Evaluate Vatiquinone in Friedreich #Ataxia.

The Phase 3 MOVE-FA trial is an 18-month parallel arm, placebo-controlled study evaluating vatiquinone versus placebo in approximately 110 children and young adults with FA. The primary endpoint is the change from baseline in the modified Friedreich ataxia rating scale (mFARS), with key secondary endpoints assessing ambulation and activities of daily living (incl #speech). This endpoint strategy was developed in consultation with both the FDA and European Medicines Agency. The study will include sites in the U.S., E.U., Australia and Latin America.

Click here for more details.

Related Post

  • Posted on 28 November, 2021
    Dr Garcia joins the Redenlab science team to drive its language analytics pipeline for cognitive-linguistic disorders like fronto-temporal dementia. Adolfo...
    • Posted on 21 July, 2021
      The ARC Training Centre for Optimal Ageing aims to address issues identified by older adults as essential for quality of...
      • Posted on 20 July, 2021
        Redenlab Inc. are pleased to announce securing clinical trial in Cyclic Vomiting Syndrome with a Top 10 pharma company. Redenlab...